May. 2 at 4:34 PM
$CSBR No offering as they have
$8M+ in cash after collecting the
$5M license payment. There's a large seller. Company is in an odd place between current revenues coming from transgenic mouse testing (which the FDA is moving away from) and AI modeling (where
$CSBR has the best oncology preclinical modeling datasets around). CRO revenues will continue to be strong on top of license deals selling datasets before world is ready for AI replacing animal testing in oncology . Trading at a 35% discount to
$CRL even after both getting crushed.
